Breaking News Headlines Today | Ground News

See every side of every news story

biopharmadive.com image

News from biopharmadive.com

The Ground News media bias check for biopharmadive.com is Center. Scores are assigned by aggregating bias scores from Ad Fontes Media, Media Bias/Fact Check, and AllSides.

biopharmadive.com’s aggregated factuality score is High. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about biopharmadive.com

Where is biopharmadive.com located?biopharmadive.com's Website

Media Bias Ratings

Average Bias Rating:

Center

Center

byMedia Bias/Fact Check

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top biopharmadive.com News

Lilly's Jaypirca (Pirtobrutinib) Met Its Primary Endpoint in First-of-Its-Kind, Head-to-Head Phase 3 Study versus Imbruvica (Ibrutinib)

Eli Lilly · Indianapolis

Lilly's Jaypirca (Pirtobrutinib) Met Its Primary Endpoint in First-of-Its-Kind, Head-to-Head Phase 3 Study versus Imbruvica (Ibrutinib)

65% Center coverage: 26 sources

In addition to meeting the primary endpoint of non-inferiority for overall response rate (ORR) in the BRUIN CLL-314 study, pirtobrutinib achieved a numerically higher ORR of 87.0% compared to 78.5% for ibrutinib in the intent-to-treat (ITT) population See the Story

Bispecific Trial in Myeloma Sparks Talks of 'Functional Cure'

Cancer · Orlando

Bispecific Trial in Myeloma Sparks Talks of 'Functional Cure'

100% Center coverage: 3 sources

(MedPage Today) -- ORLANDO -- Combining teclistamab (Tecvayli) with subcutaneous daratumumab-hyaluronidase (Darzalex Faspro) significantly improved progression-free survival (PFS) and overall survival (OS) in patients with relapsed/refractory...See the Story

Pfizer’s Appetite for More Obesity Meds Leads to $150M Deal for Oral GLP-1 Drug From China

Obesity · China

Pfizer’s Appetite for More Obesity Meds Leads to $150M Deal for Oral GLP-1 Drug From China

100% Center coverage: 2 sources

YaoPharma’s once-daily oral GLP-1 drug is currently in Phase 1 testing. The license agreement gives Pfizer global rights to the small molecule, which it envisions as part of potential drug combinations. The post Pfizer’s Appetite for More Obesity Meds Leads to $150M Deal for Oral GLP-1 Drug From China appeared first on MedCity News.See the Story

Breaking News Topics Related to biopharmadive.com